Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Medical oncology (Northwood, London, England)

Volumn 31, Issue 2, 2014, Pages

  Suspitsin, Evgeny N ^a   Yanus, Grigory A ^b   Sokolenko, Anna P ^b   Yatsuk, Olga S ^b   Zaitseva, Olga A ^b   Bessonov, Alexandr A ^b   Ivantsov, Alexandr O ^b   Heinstein, Valeria A ^b   Klimashevskiy, Valery F ^b   Togo, Alexandr V ^b   Imyanitov, Evgeny N ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOM SYNDROME HELICASE; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN; RECQ HELICASE; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; MUTATION; PATHOLOGY; PROGNOSIS;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CHECKPOINT KINASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; RECQ HELICASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84905914908     PISSN: None     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0828-9     Document Type: Article

References (0)